280761-97-9

Usage

Uses

Used in Organic Synthesis:
9-Boc-7-oxa-9-azabicyclo[3.3.1]nonan-3-one is used as a building block in organic synthesis for its ability to form a wide range of compounds with specific properties and functions. Its unique structure allows for the development of new molecules with potential applications in various fields.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 9-Boc-7-oxa-9-azabicyclo[3.3.1]nonan-3-one is utilized as a versatile intermediate for the synthesis of pharmaceuticals. Its structural features enable the creation of molecules with targeted therapeutic effects, contributing to the development of new drugs and treatments.
Used in Chemical Research:
9-Boc-7-oxa-9-azabicyclo[3.3.1]nonan-3-one plays a significant role in chemical research, where it is employed to explore new reaction pathways and mechanisms. Its unique structure provides opportunities for studying various chemical transformations and understanding the underlying principles of organic chemistry.
Used in Drug Development:
In the process of drug development, 9-Boc-7-oxa-9-azabicyclo[3.3.1]nonan-3-one is an important compound for the synthesis of potential drug candidates. Its versatility in forming different molecular structures allows researchers to optimize the properties of new drugs, enhancing their efficacy and safety profiles.
Overall, 9-Boc-7-oxa-9-azabicyclo[3.3.1]nonan-3-one is a crucial compound in the fields of organic synthesis, medicinal chemistry, chemical research, and drug development, owing to its unique structure and versatility in creating a wide range of biologically active molecules.

Upstream product

• 926658-87-9 3-oxa-9-azabicyclo[3.3.1]nonan-7-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 81514-40-1 N-benzyl-7-oxa-9-azabicyclo<3.3.1>nonan-3-one 
• 1126795-00-3 3-oxa-9-azabicyclo[3.3.1]nonan-7-one hydrochloride 

Downstream Products

• 1148006-31-8 (1R,5S,7S)-tert-butyl 7-hydroxy-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate 
• 1126795-00-3 3-oxa-9-azabicyclo[3.3.1]nonan-7-one hydrochloride 
• 1361297-75-7 5-(3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-3-(6-phenylpyridin-3-yl)-8,9-dihydropyrazolo[1,5-a]pyrido[3,2-e]pyrimidin-6(7H)-one 
• 1319256-94-4 tert-butyl 7-(7-(bis((2-(trimethylsilyl)ethoxy)methyl)amino)-6-(1-ethoxyvinyl)-3-(6-phenylpyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yI)-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate 
• 1319256-93-3 tert-butyl 7-(7-(bis((2-(trimethylsilyl)ethoxy)methyl)amino)-6-bromo-3-(6-phenylpyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate 
• 1319256-92-2 tert-butyl 7-(7-(bis((2-(trimethylsilyl)ethoxy)methyl)amino)-3-(6-phenylpyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate 
• 1313034-29-5 tert-butyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-oxa-9-azabicyclo[3 .3.1]non-6-ene-9-carboxylate 

Relevant academic research and scientific papers

SUBSTITUENT-INCLUDING UREA COMPOUND

An object of the present invention is to provide a compound that has a specific chemical structure having an activation effect on SIRT6 and is useful as an active component for preventing and treating inflammatory diseases. The present invention relates to a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof. (Each symbol in Formula (1) has the same definition as that described in the specification.)

THERAPEUTICALLY ACTIVE BICYCLIC-SULPHONAMIDES AND PHARMACEUTICAL COMPOSITIONS

Pharmaceutical compounds have a bicyclic-sulphonamide structure and pharmaceutical compositions including the compounds may be used in therapy as brain-cell-death protectants and may be used, for example, in the treatment of chronic neurodegenerative diseases. The compounds are active as inhibitors of N-acylethanolamine-hydrolysing acid amidase (NAAA) and may be used for the therapeutic treatment and prevention of pain and inflammatory disorders and other disorders which benefit from the modulation of fatty acid ethanolamides, particularly palmitoylethanolamide (PEA).

3-OXA-8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AND THIER USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES

A compound of formula Ia, Ib, Ic or Id: wherein: n is 1 or 2;R N is H or Me; R1 is optionally one or more halo or methyl groups;R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H;(iii) Me; and (iv) CH2 OH; R 2c and R 2d (if present) are independently selected from the group consisting of: (i) F; (ii) H;(iii) Me; and(iv) CH 2 OH;R 3a and R 3b are independently selected from H and Me; R 4a is selected from OH,-NH 2, -C(=O)NH 2, and -CH 2 OH; R 4b is either H or Me; R5 is either H or Me; m is 1 or 2; q is 0 or 1;R 11a, R 11b, R 11c and R 11d are independently selected from H, halo, C1-4 alkyl, C 1-4 fluoroalkyl, C 3-4 cycloalkyl, C 1-4 alkyloxy, NH-C 1-4 alkyl and cyano; R 12a and R 12b are independently selected from the group consisting of: (i) F; (ii) H;(iii) Me; and (iv) CH 2 OH; R 12c and R 12d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH 2 OH;R 12e is H or Me; R 13a and R 13b are independently selected from H and Me; R 14 is either H or Me; R 16a and R 16b are independently selected from H and Me; R 6 is selected from H, OMe, and OEt.

PYRIMIDINE DERIVATIVES AS GPCR MODTTLATORS FOR USE IN THE TREATMENT OF OBESITY AND DIABETES

The present invention relates to Pyriraidine Derivatives of formula (I), compositions comprising a Pyrimidine Derivative, and methods of using the Pyrimidine Derivatives for treating or preventing obesity, diabetes, a diabetic complication, a metabolic di